作者
Hongyan Li, Menghan Gao, Hailong You, Peng Zhang, Yuchen Pan, Nan Li, Ling Qin, Heyuan Wang, Dan Li, Yang Li, Hongmei Qiao, Lina Gu, Songbai Xu, Weiying Guo, Nanya Wang, Chaoying Liu, Pujun Gao, Junqi Niu, Jie Cao, Yang Zheng
发表日期
2023/2/1
期刊
Clinical Infectious Diseases
卷号
76
期号
3
页码范围
e148-e154
出版商
Oxford University Press
简介
Background
Acceleration of negative respiratory conversion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with coronavirus disease 2019 (COVID-19) might reduce viral transmission. Nirmatrelvir/ritonavir is a new antiviral agent recently approved for treatment of COVID-19 that has the potential to facilitate negative conversion.
Methods
A cohort of hospitalized adult patients with mild-to-moderate COVID-19 who had a high risk for progression to severe disease were studied. These patients presented with COVID-19 symptoms between 5 March and 5 April 2022. The time from positive to negative upper respiratory reverse transcription-polymerase chain reaction (RT-PCR) conversion was assessed by Kaplan-Meier plots and Cox proportional hazards regression with the adjustment for patients’ baseline demographic and clinical characteristics …
学术搜索中的文章
H Li, M Gao, H You, P Zhang, Y Pan, N Li, L Qin… - Clinical Infectious Diseases, 2023